Bellevue Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $221M | Sell |
|
|||||
|
2025
Q1 | $207M | Sell |
|
|||||
|
2024
Q4 | $181M | Sell |
|
|||||
|
2024
Q3 | $223M | Sell |
|
|||||
|
2024
Q2 | $224M | Buy |
|
|||||
|
2024
Q1 | $137M | Buy |
|
|||||
|
2023
Q4 | $169M | Sell |
|
|||||
|
2023
Q3 | $158M | Sell |
|
|||||
|
2023
Q2 | $171M | Buy |
|
|||||
|
2023
Q1 | $177M | Sell |
|
|||||
|
2022
Q4 | $219M | Sell |
|
|||||
|
2022
Q3 | $192M | Sell |
|
|||||
|
2022
Q2 | $154M | Sell |
|
|||||
|
2022
Q1 | $201M | Sell |
|
|||||
|
2021
Q4 | $226M | Sell |
|
|||||
|
2021
Q3 | $266M | Sell |
|
|||||
|
2021
Q2 | $263M | Sell |
|
|||||
|
2021
Q1 | $230M | Buy |
|
|||||
|
2020
Q4 | $208M | Buy |
|
|||||
|
2020
Q3 | $227M | Sell |
|
|||||
|
2020
Q2 | $238M | Sell |
|
|||||
|
2020
Q1 | $193M | Sell |
|
|||||
|
2019
Q4 | $215M | Sell |
|
|||||
|
2019
Q3 | $158M | Buy |
|
|||||
|
2019
Q2 | $140M | Buy |
|
|||||
|
2019
Q1 | $25M | Buy |
|
|||||
|
2018
Q4 | $16.4M | Buy |
|
|||||
|
2018
Q3 | $19.2M | Buy |
|
|||||
|
2018
Q2 | $10.2M | Buy |
|
|||||
|
2018
Q1 | $2.59M | Sell |
|
|||||
|
2017
Q4 | $2.81M | Sell |
|
|||||
|
2017
Q3 | $8.88M | Sell |
|
|||||
|
2017
Q2 | $9.97M | Sell |
|
|||||
|
2017
Q1 | $7.27M | Buy |
|
|||||
|
2016
Q4 | $899K | Hold |
|
|||||
|
2016
Q3 | $1.63M | Hold |
|
|||||
|
2016
Q2 | $1.33M | Hold |
|
|||||
|
2016
Q1 | $1.51M | Buy |
|